Skip to main content

Table 1 Summary of pharmacokinetic characteristics of rivaroxaban at steady state based on phase II data

From: Laboratory assessment of rivaroxaban: a review

Parameter Rivaroxaban dose
  2.5 mg bid* 2.5 mg bid# 5 mg bid* 10 mg bid* 20 mg bid* 30 mg bid
AUC (μg.h/l) 300 328 464 974 1764 6500
Cmax (μg/l) 53 40 86 180 299 400
Ctrough (μg/l) 8 14 11 38 68 160
  1. *Data are mean values from an analysis of the ODIXa-HIP2 study [17]. #Data are median values from an analysis of the ATLAS ACS TIMI 46 study (subset of patients aged <50 years) [18]. Data are mean values from an analysis of the ODIXa-DVT study [19].
  2. Abbreviations: AUC area under the concentration–time curve, bid twice daily, C max maximum plasma concentration, C trough minimum plasma concentration.